FHTX 8-K 2026-10-01
Foghorn Therapeutics Inc. (FHTX) 8-K dated 2026-10-01 — accession 0001628280-26-064102.
Foghorn Therapeutics Inc. (FHTX) is a biotechnology company listed on NASDAQ.
Foghorn Therapeutics Inc. filed a 8-K on 2026-10-01. Accession 0001628280-26-064102.
This 8-K covers: Exit or restructuring costs (Item 2.05), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported FHTX revenue for 2025-12-31 was $30.9M. Net income was -$74.3M. Revenue was up 36.8% from 2024-12-31 to 2025-12-31. FHTX currently screens at market cap $237.8M.
Not investment advice. The FHTX SEC hub lists recent forms. The stock page is the research view.